Xiaoxia Li,Caini Liu,Junpeng Deng,Thomas A. Hamilton,Jarod Zepp
申请号：
US15477410
公开号：
US20170298095A1
申请日:
2017.04.03
申请国别(地区):
US
年份:
2017
代理人:
摘要：
A method of treating an IL-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the SEFIR domain of IL-17R to the SEFIR domain of Act1. In particular, it has been determined that the αC helix region of the SEFIR domain of both IL-17R and Act1 plays an important role in the association of IL-17R and Act1. To facilitate cell permeation, the decoy peptide is preferably conjugated to a protein transduction domain. Examples of IL-17 mediated diseases include various human and animal inflammatory and autoimmune diseases such as asthma.
